Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Patent Rules May Tighten Following AstraZeneca Losec Abuse Case

This article was originally published in The Pink Sheet Daily

Executive Summary

The Opinion of the Advocate General of the Court of Justice of the European Union that AstraZeneca tried to hold generic omeprazole off the market could make patent acquisitions more difficult and could impede pharmaceutical innovation.

You may also be interested in...

AstraZeneca's ECJ Setback May Impact European IP Protection Strategies

The European Court of Justice sides with the European Commission: manipulating the patent and regulatory systems to block competitors gets AZ a slap on the wrist and serves as a warning to others.

Quelle Surprise! EU Investigators Raid Pharma Firms

Government officials investigate possible obstacles to competition in the drug industry, expect a preliminary report this fall.

MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts